A Weight Loss Pill Is Here. Here’s What To Know.
There’s another GLP-1 on the market and this is big news - because it’s a pill! This newly FDA-approved oral GLP-1 (Foundayo/orforglipron) is a once-daily pill that can be taken without timing around food or water. It belongs to the same family as drugs like Wegovy and Zepbound. In clinical trials, patients on higher doses saw meaningful weight loss, with averages around the mid-20 pound range when combined with lifestyle changes. Like the others, this medication works by targeting appetite regulation and metabolic signaling, helping patients feel fuller, eat less, and improve blood sugar control. It’s approved for adults with obesity or those with related medical conditions.
No more injections
Many patients are hesitant about injections, and even those who aren’t often struggle with consistency. A once-daily oral option removes that barrier and makes treatment more accessible. Of course results depend heavily on adherence, dosing, and lifestyle. But, in obesity medicine, the biggest issue isn’t usually starting a medication, it’s staying on it. When something has to be taken around a bunch of rules, people fall off, not because they don’t care, but because life gets in the way. A pill just fits better into a normal routine. And when it’s easier to take, people are more likely to actually stay consistent with it.
Foundayo in trials
ATTAIN 1 trial: 3127 patients underwent randomization to treatment with orforglipron vs placebo over 72 weeks. The mean change in body weight from baseline:
-7.5% with 6 mg of orforglipron
-8.4% with 12 mg
-11.2% with 36 mg
as compared with -2.1% (with placebo)
Pricing for Foundayo
Currently, pricing varies by dose, with lower doses starting around $149/month and higher doses reaching close to $300/month for self-pay, though costs may be lower with insurance coverage or manufacturer programs. I personally was hoping for even more affordability, but soon Medicare patients will pay $50/mo (I hope!).
What to consider before taking Foundayo
There is no single intervention that replaces the foundation. If you are considering a medication like this, the conversation should not just be “Does it work?” but: “Is it appropriate for me? What are the risks? And what does long-term management actually look like?” The goal should never be short-term weight loss. It’s sustainable metabolic health over time.
It’s also very important to remember that these medications help regulate appetite and reduce the biological drive to overeat, but they do not replace the need for structure, nutrition, and movement. Without those, the results are often limited or difficult to maintain. There are also side effects to consider. The most common are gastrointestinal, things like nausea, changes in bowel habits, and abdominal discomfort. For most patients these are manageable, but they still matter when deciding whether this is the right option.
Foundayo/orforglipron will be a good option for people in maintenance switching from injections of both Wegovy and Zepbound. At a lower cost point, they can expect to regain only close to 1 kg switching from Wegovy to Foundayo and about 5 kg switching from Zepbound. At 52 weeks, participants switching to orforglipron maintained their prior weight loss, with an average difference of 0.9 kg for individuals who switched from semaglutide (Wegovy) and 5.0 kg for those from tirzepatide (Zepbound).
Subscription-style model for Wegovy
Since we’re on the topic of GLP1s, I think it’s worth mentioning that Novo Nordisk is rolling out a new subscription-style model for Wegovy aimed at lowering costs for patients paying out of pocket, with flat monthly pricing even as doses change. However, these reduced prices are currently being offered through select telehealth platforms rather than traditional physician practices. Lower prices are great news, but - as a physician, I have to ask - why are these prices only available through online programs? They aren’t currently available to physicians or (ABOM) Obesity certified physicians’ patients! It’s frustrating to see access expanding, but not through the providers who are actually trained to manage these medications long term. I don’t have a clear answer to this, but if you’re looking for a more personalized, medically guided approach, I invite you to connect with my team at Radiant Health Dallas. Access should come with expertise, not replace it.